Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Liabilities and Shareholders Equity (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Liabilities and Shareholders Equity for 10 consecutive years, with $30.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 54.92% year-over-year to $30.2 million, compared with a TTM value of $198.2 million through Dec 2025, down 38.34%, and an annual FY2025 reading of $30.2 million, down 54.92% over the prior year.
  • Liabilities and Shareholders Equity was $30.2 million for Q4 2025 at VYNE Therapeutics, down from $44.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $149.2 million in Q1 2021 and bottomed at $19.3 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $67.9 million, with a median of $65.6 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 58.81% in 2022, then soared 295.48% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $67.0 million in 2021, then crashed by 39.21% to $40.8 million in 2022, then skyrocketed by 139.67% to $97.7 million in 2023, then tumbled by 31.51% to $66.9 million in 2024, then tumbled by 54.92% to $30.2 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for VYNE at $30.2 million in Q4 2025, $44.7 million in Q2 2025, and $56.4 million in Q1 2025.